MedTrace Logo

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

NCT00424866 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-11-01

No results posted yet for this study

Summary

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Conditions

  • Peripheral Arterial Disease
  • Stenosis
  • Intermittent Claudication

Interventions

DRUG

FGF-1

Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg

DRUG

Placebo

Vehicle: 0 µg/kg

Sponsors & Collaborators

  • CardioVascular BioTherapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-12-31
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424866 on ClinicalTrials.gov